September 15, 2024
BARCELONA — Adding lenvatinib and pembrolizumab to transarterial chemoembolization (TACE) led to a significant improvement in progression-free survival in patients with intermediate-stage hepatocellular carcinoma compared with […]
September 14, 2024
BARCELONA — The combination of standard FOLFOX chemotherapy with doublet immunotherapy did not improve progression-free survival compared with chemotherapy alone in patients with HER2-negative gastric or gastroesophageal […]
September 14, 2024
Adjuvant durvalumab (Imfinzi) provided no significant improvement in disease-free survival compared with placebo following resection in patients with early-stage non-small cell lung cancer (NSCLC), according to […]
September 14, 2024
BARCELONA – Adding preoperative chemoradiation to standard-of-care perioperative chemotherapy did not improve overall or progression-free survival in patients with resectable adenocarcinoma of the stomach or gastroesophageal […]
September 14, 2024
The US Food and Drug Administration (FDA) has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for the treatment of adults and children age 12 years […]
September 13, 2024
The US Food and Drug Administration (FDA) has approved a subcutaneous formulation of the anti-CD20 antibody ocrelizumab (Ocrevus Zunovo, Genentech) for the treatment of relapsing multiple […]
September 13, 2024
BARCELONA — In a first-in-human clinical trial, an investigational messenger RNA (mRNA)-based cancer vaccine for glioblastoma induced tumor-associated antigen-specific T-cell responses in more than three quarters […]
September 13, 2024
US suicide rates have reached alarming levels, with data from Centers for Disease Control and Prevention (CDC) showing a 37% increase from 2000 to 2022. Nearly […]
September 13, 2024
TOPLINE: Amyloid pathology typical of Alzheimer’s disease (AD) is 50% lower in patients with multiple sclerosis (MS) than in those without the condition, an analysis of […]
Prev page
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434
Next page